Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III lomustine + temozolomide versus standard temozolomide in newly diagnosed MGMT-methylated IDH-wildtype glioblastoma with optional TTFields
2023-506998-35-00Phase 3Authorised
- Sponsor
- Region Västra Götaland
- Start
- Jan 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial in glioblastoma (GBM) comparing Lomustine + temozolomide with Standard temozolomide (2 arms). Primary endpoint: Overall survival. Planned start Jan 2025; status: authorised.
02
Drugs
lomustinetemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2023-506998-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506998-35-00.